Summary
This prediction ended on 07.06.18 with a price of €27,600,000. With a performance of -9.21%, the BUY prediction for Neovacs by melinda closed slightly in the red. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Neovacs | - | - | - | - |
| iShares Core DAX® | 0.795% | 1.458% | 17.980% | 69.888% |
| iShares Nasdaq 100 | -3.088% | -0.762% | 3.169% | 101.814% |
| iShares Nikkei 225® | -0.952% | -2.268% | 12.208% | 45.300% |
| iShares S&P 500 | -1.393% | 0.199% | 1.698% | 63.763% |
According to melinda what are the pros and cons of Neovacs for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Neovacs diskutieren
Neovacs: Beginn der Spekulation vor klinischen Ergebnissen für LUPUS?

(Vom Mitglied beendet)


